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The objective of this research work was to design, develop and optimize the self micro-emulsifying 
drug delivery system (SMEDDS) of Felodipine (FL) filled in hard gelatine capsule coated with polymer 
in order to achieve rapid drug release after a desired time lag in the management of hypertension. 
Microemulsion is composed of a FL, Lauroglycol FCC, Transcutol P and Cremophor EL. The optimum 
surfactant to co-surfactant ratio was found to be 2:1. The resultant microemulsions have a particle size 
in the range of 65-85 nm and zeta potential value of -13.71 mV. FL release was adequately adjusted by 
using pH independent polymer i.e. ethyl cellulose along with dibutyl phthalate as plasticizer. Influence 
of formulation variables like viscosity of polymer, type of plasticizer and percent coating weight gain 
was investigated to characterize the time lag. The developed formulation of FL SMEDDS capsules 
coated with ethyl cellulose showed time lag of 5-7 h which is desirable for chronotherapeutic application.
Uniterms: Felodipine/self-microemulsifying delivery. Felodipine/chronotherapeutic application. Self-
microemulsifying drug delivery system/development. Drugs/controlled release. Ethyl cellulose/drugs 
coated. Hypertension/treatment. Chronotherapeutics/hypertension treatment.
O objetivo desse trabalho de pesquisa foi planejar, desenvolver e otimizar sistema de liberação de 
fármaco auto-microemulsificante(SMEDDS) de felodipino (FL) em cápsulas de gelatina dura revestidas 
com polímero, a fim de obter liberação rápida após tempo desejado no manejo da hipertensão. A 
microemulsão é composta de FL, lauroglilcol FCC, Transcutol P e Cremophor EL. A proporção ótima 
de tensoativo e de co-tensoativo foi de 2:1. As microemulsões resultantes têm tamanho de partícula na 
faixa de 65-85 nm com potencial zeta de -13,71 mV. A liberação de FL foi ajustada adequadamente, 
utilizando-se polímero independente de pH, como etilcelulose com ftalato de dibutila como plastificante. 
A influência das variáveis da formulação, como viscosidade do polímero, tipo de plastificante e ganho 
percentual de peso do revestimento foi investigada para caracterizar o intervalo de tempo de liberação. 
A formulação de cápsulas de FL SMEDDS revestidas com etilcelulose mostrou intervalo de tempo de 
liberação de 5 a 7 horas, o que é desejável para uma aplicação cronoterapêutica.
Uniterms: Felodipino/liberação de fármaco auto-emulsificante. Felodipino/aplicação cronoterapêutica. 
Sistema de liberação de fármaco auto-emulsificante/desenvolvimento. Fármacos/liberação controlada. 
Etilcelulose/revestimento de fármacos. Hipertensão/tratamento. Cronoterapia/tratamento da hipertensão.
INTRODUCTION
The key to the success of any drug delivery system 
depends upon the development of formulations that 
accomplish the therapeutic needs associated with particular 
pathological condition or disease state (Lemmer, 1991). It 
has been observed that many physiological functions (e.g. 
blood pressure, hormonal levels) and pathophysiological 
disease states (e.g. hypertension, myocardial infarction, 
cancer, bronchial asthma and rheumatic disease) show a 
circadian pattern in their manifestations i.e. the disease 
symptoms do not occur evenly for the twenty-four 
hours of the day but undergo significant daily variations 
(Lemmer, 2012; Francis et al., 2010). Therefore, the 
ideal remedy for such disease states should preferentially 
involve formulations that release drugs after a specified 
delay period (lag period-time of no drug release) after 
dosing by the patient (Michael et al., 2007). Thus, drug 
release from the formulation will be targeted to a specific 
period of the day when there is higher chances of clinical 
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manifestation of the disease. Such a delivery approach is 
termed as chronotherapeutic (chronos-time) (Mandal et 
al., 2010; Youan, 2004).
Hypertension is a common chronic condition 
affecting up to 35% of human adults and showed 
circadian variation in manifestations (Hermida et al., 
2007). Cardiovascular events happen more often in the 
morning, and ambulatory blood pressure (BP) exhibits a 
diurnal variation with increase in the morning (morning 
BP surge). The morning BP surge was reported to be 
associated with high risk of cardiac death, and ischemic 
and hemorrhagic stroke (Nayak et al., 2009; Cohen et al., 
1997; Behrens et al., 1997). Blood pressure which arises 
notably just before waking up is usually responsible for 
these attacks and deaths (Karavas et al., 2006). Therefore, 
the chronotherapeutic drug delivery approach should be 
the ideal remedy for the treatment of hypertension in order 
to tackle the early morning mortality associated with such 
disease state.
Felodipine (FL), which is used in the proposed 
research, belongs to a category of dihydropyridine 
derivative. It is chemically described as ethylmethyl-4-(2,3-
dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridine-
carboxylate [USP (United States Pharmacopoeia 29). FL 
is a calcium antagonist used commonly for its excellent 
antihypertension and antianginal effects (Teberekidis et 
al., 2007). FL is a poorly water soluble drug belonging 
to the category of BCS class II (Yasir et al., 2010). The 
bioavailability of FL is strongly limited by its high lipophilic 
character (aqueous solubility <0.5 mg/L) (Abrahamsson et 
al., 1994). Literature reports the chronotherapeutic drug 
delivery of FL using polyvinyl pirrolidone/hydroxypropyl 
methylcellulose (PVP/HPMC) nanodispersion which is 
responsible for bioavailability enhancement of FL (Lemmer, 
1991; Evangelos et al., 2006) and also the extended release 
FL self-nanoemulsifying system (Patil et al.,2009). Thus, 
effective formulation design can be a useful approach 
which results in improved solubility, absorption and in 
total oral bioavailability of such drug candidates (Pouton 
et al., 2006). There are the several formulation approaches 
to increase the solubility of poorly water soluble drugs like 
cyclodextrin, nanosponges and nanoparticles (Khalid et al., 
2011; Khalid et al., 2011; Satyen et al. 2010; Francesco et 
al., 2011; Ridhurkar et al., 2012; Nekkanti et al., 2011). 
However, Self-microemulsifying drug delivery systems 
(SMEDDS) are among the methods used to improve the 
oral bioavailability of poorly soluble drugs (Hong et al., 
2006). SMEDDS comprise isotropic mixtures of natural 
or synthetic oils with surfactants and co-surfactants. 
These systems spontaneously emulsify when exposed 
to gastrointestinal (GIT) fluids to form oil in water 
microemulsion with nanometric droplet size, in the range of 
20–200 nm (Basalious et al., 2010). Furthermore, they can 
improve oral bioavailability through enhancing permeation 
across the intestinal membrane, solubilization, droplet size 
reduction and improvement of drug dissolution (Wang et al., 
2010; Wasan et al., 2009). Self-microemulsifying system 
of FL would be an efficient, convenient and more patient 
compliant approach as SMEDDS can be filled in hard 
gelatine capsules due to their anhydrous nature enabling its 
administration as unit dosage form.
In the present work, FL SMEDDS was prepared 
which was subsequently used in chrono-capsules 
formulation. The objectives of the present study were, first, 
to develop a SMEDDS of FL to increase the bioavailability 
and to formulate time delayed chronotherapeutic capsule 
formulation of FL using pH independent polymer as a 
functional coating material. Different viscosity grades of 
ethyl cellulose along with hydrophobic plasticizer will be 
used as functional coating material. Such a hydrophobic 
coating layer will act as an alarm clock releasing the drug 
amount from the active core at the predictable time.
MATERIAL AND METHODS
Raw Material
Felodipine (FL) was procured from Nivedita 
Chemicals Pvt. Ltd. (Mumbai, India). Cremophor EL 
(CEL) (BASF, Mumbai, India), Transcutol P (TP) (BASF, 
Mumbai, India), Lauroglycol FCC (LFCC) (Colorcon 
Asia Pvt. Ltd., Mumbai, India), Ethyl cellulose (EC N7, 
EC N10, EC N22) (Colorcon Asia Pvt. Ltd., Mumbai, 
India) and Hard gelatin capsules (Associated Capsules, 
Mumbai, India) were obtained as gift samples. All other 
chemicals and reagents were of analytical grade. HPLC 
grade solvents were used in case of HPLC analysis. 
Milli-Q water was used in all experiments.
Methods
Solubility studies
Solubility of FL in various components (oils, 
surfactants and co-surfactants) was determined. Briefly, 
500 mg of each of the selected vehicle were added in 
vial containing an excess of FL (1 gram). After sealing 
the vial, the mixtures were shaken at 30 ± 0.5 ºC for 
48 h with thermostatically controlled water bath shaker 
(Remi, India). After 48 h, the mixtures were centrifuged at 
3000 rpm for 5 min (Research Compufuge, Remi, India) 
and an excess insoluble FL was discarded by filtration 
using a membrane filter (0.45 µm, 13 mm, Whatman, 
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USA). Concentration of FL in each component was 
quantified by HPLC. The analysis was carried out on a 
Waters 717 autosampler chromatographic system (Waters, 
India) equipped with waters 515 HPLC pump and waters 
2487 dual wavelength detector using Lichrosphere C-18 
Merck (250 mm × 4.6 mm; 5 µm) (Thermoelectron, 
USA) at a flow rate of 1.0 mL/min [Mobile Phase- 
buffer: acetonitrile: methanol (40:40:20] (USP 29). The 
analysis was carried out at 254 nm. The linearity of FL 
was accomplished in the range of 240-360 µg/mL. The 
HPLC chromatogram of drug showed very sharp peak at 
retention time of 20.288 min (Figure 1). Each experiment 
was carried out in triplicate. The components showing 
maximum solubilization were selected for further studies.
Selection of surfactant to co-surfactant ratio
Ratio of surfactant to co-surfactant is an important 
consideration for formulating microemulsion based system. 
Cremophor EL (CEL) as a surfactant and Transcutol P (TP) 
as a co-surfactant were used during the study. Turbidimetric 
method was used to assess relative efficacy of the co-
surfactant to improve the microemulsification ability of 
the surfactants and to select best one from the large pool 
of co-surfactants available for peroral delivery (Date et 
al., 2007). CEL: TP (2:1 v/v) was mixed with oil and the 
mixture was homogenized with the aid of the gentle heat 
(40-50 °C). The isotropic mixture was accurately weighed 
and diluted to 50 mL with water to yield fine emulsion. 
The ease of formation of emulsion was observed by noting 
the number of volumetric flask inversions required to give 
uniform emulsion. The resulting emulsions were observed 
visually for the relative turbidity.
Preparation of SMEDDS
SMEDDS containing FL was prepared by mixing oil 
phase with surfactant and co-surfactant using vortex mixer. 
Oil Phase i.e. lauroglycol FCC (LFCC) was accurately 
weighed and transferred into microemulsion tube followed 
by addition of surfactant (CEL) and co-surfactant (TP) 
in order to prepare blank SMEDDS. Concentration of 
the three components totalled to 100%. Drug loaded 
SMEDDS were prepared by keeping drug content constant 
as 0.1 mg/g of the prepared SMEDDS. The composition 
of FL SMEDDS formulation is given in Table I.
Self emulsification and flowability
Evaluation of self-emulsifying properties of 
SMEDDS formulation was carried out by visual 
assessment as previously reported (Khoo et al., 1998). 
Briefly, different compositions having oil and different 
surfactant to co-surfactant ratios of were categorized 
on apparent clarity of the resultant emulsion. Visual 
assessment was performed by drop wise addition of the 
pre-concentrate (SMEDDS) into 250 mL water. This was 
performed in a glass beaker at room temperature and the 
contents were gently stirred magnetically at approximately 
100 rpm. The compositions were categorized based on the 
TABLE I - Composition of felodipine SMEDDS formulation
Components Amount (mg)
Felodipine 10
Lauroglycol FCC 40
Cremophor EL: Transcutol P (2:1 v/v) 60
FIGURE 1 – HPLC Chromatogram of standard drug.
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appearance of resultant emulsion as clear (transparent with 
bluish tinge) and non-clear (turbid). Compositions were 
also evaluated for flowability by visual observation as 
the final aim was to fill the formulation into Hard Gelatin 
Capsules (HGCs).
Construction of Pseudo ternary phase diagram
Pseudo-ternary phase diagrams of oil, surfactant: 
co-surfactant and water were developed using water 
titration method. Mixtures of oil and surfactant to co-
surfactant at certain weight ratios were diluted with 
water in a drop wise manner. For each phase diagrams 
at a specific ratio of surfactant to co-surfactant (S/
CoS), 2:1, 1.5:1, 1:1 and 0.5:1 (w/w), transparent and 
homogenous mixture of oil and S/CoS were formed by 
application of vortexing for 5 min. Each mixture was 
further titrated with water and visually observed for 
phase clarity and flowability. The concentration of water 
at which turbidity-to-transparency and transparency-
to-turbidity transitions occurred were derived from the 
weight measurements. These values were then used to 
determine the boundaries of the microemulsion domain 
corresponding to the chosen value of oils, as well as 
the S/CoS mixing ratio. Phase diagrams were then 
constructed using Tri plot v1-4 software.
Evaluation of FL loaded SMEDDS
Optimized SMEDDS formulations were evaluated 
for robustness to dilution, globule size, in-vitro dissolution 
profile and dispersion time and precipitation.
•	 Robustness to dilution
Robustness of FL SMEDDS to dilution was studied 
by diluting it to 50, 100 and 1000 times with various 
dissolution media viz. water, buffer pH 1.2, buffer pH 4.5 
and buffer pH 6.8. The diluted microemulsions were stored 
for 12 h and observed for any signs of phase separation or 
drug precipitation.
•	 Emulsion droplet size analysis of FL SMEDDS
The size of FL SMEDDS formulations were 
determined by Delsa™Nano C (Beckman Coulter, USA). 
SMEDDS formulation (100 mg) was diluted with water 
to 500 ml in a beaker and gently mixed using a glass rod. 
The resultant emulsion was further subjected to droplet 
size analysis using DelsaTM Nano.
•	 Determination of zeta potential
Zeta potential was measured by using DelsaTM 
Nano C (Beckman Coulter, USA). SMEDDS formulation 
(100 mg) was diluted with water to 500 mL in a beaker 
and analyzed for zeta potential measuring instrument. All 
measurements were carried out at 25 °C
•	 Dispersion time and precipitation assessment
Dispersion time is defined as the time taken for lipid 
or surfactant based system to disperse in the dispersion 
medium (Khoo et al., 1998). In case of SMEDDS, it 
determines the time taken for pre-concentrate to form a 
well-dispersed, clear microemulsion. Dispersion time was 
determined using USP XXIV type 2 apparatus. Medium 
used for study was water and 0.1 N hydrochloric acid 
(HCl) (500 mL). The study was carried out by adding 
the formulation to the medium containing vessels and 
noting the time taken to form clear dispersion. The paddle 
shafts were rotated at 25 rpm to provide gentle stirring. 
Precipitation was evaluated by visual inspection of 
resultant emulsion after 24 h. The compositions were then 
categorized as stable (no precipitation at the end of 24 h) 
and unstable (precipitation).
Capsule filling
The optimized FL SMEDDS were filled as unit doses 
in HGCs of size 4 having maximum volume of 0.21 mL. 
Liquid filling was carried out at lab scale by accurately 
transferring measured dose (Formulation equivalent to 10 
mg of FL) of formulation into body of capsules followed 
by sealing. The sealing was performed using organic 
solvent ethanol.
Coating of FL SMEDDS capsules
FL SMEDDS capsules were coated with a non-
aqueous coat of 5 % w/v ethyl cellulose dispersion 
(Dispersion medium – dichloromethane (DCM): isopropyl 
alcohol (IPA). The coating was carried out a lab-scale pan 
coater (Alfred Herbert Ltd., India) previously cleaned, 
dedusted. The coating liquid was filled into the spray gun 
with the help of attachment. All the essential parameters 
for coating are shown in Table II. As the capsules rolled, 
the film forming liquid was sprayed intermittently allowing 
TABLE II - The adjusted process parameters during coating
Process variables Adjusted specifications
Pan design/Baffling 12 cm diameter with 3 baffles
Rotational Speed of Pan 30 rpm
Spray Pressure (Operational) 40 - 50 p.s.i.
Bed to Gun Distance 25 - 30 cm
Bed temperature 30 ± 5 °C
Dry air temperature 60 ± 5 °C
Spray pattern type Circular, occasionally elliptical
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the solvent to evaporate. The process was continued until 
the desired weight gain was achieved.
Effect of different grades of polymer on time lag and 
release profile
Three different grades of the hydrophobic 
polymer i.e. ethyl cellulose (N7, N10, N22) in the same 
concentration (10 mg wt. gain/capsule) were used for 
coating FL SMEDDS capsules. Coated capsules were 
evaluated for appearance, leakage, stability of cap and 
body of capsules, and drug content. Effects of these 
different grades of the coating polymer on the time lag 
and in-vitro drug release profile were studied.
Effect of different types of plasticizers on time lag and 
release profile
Different plasticizers viz. polyethyleglycol-400 
(PEG-400), triethyl citrate (TEC), diethyl phthalate (DEP) 
and dibutyl phthalate (DBP) in the same concentration 
(10% w/w of coating polymer) were used for coating FL 
SMEDDS capsules. Coated capsules were evaluated for 
appearance, leakage, stability of cap and body of capsules, 
and drug content. Effects of these different types of 
plasticizers on the time lag and in vitro drug release profile 
were studied.
Effect of coating weight gain on time lag and release 
profile
FL SMEDDS capsules were loaded with different 
weight gains of the coating polymer viz. 2.5%, 5% and 
10%. Coated capsules were evaluated for appearance, 
leakage, stability of cap and body of capsules and drug 
content. Effects of increasing coating weight gain (which 
is a function of coating thickness) on the time lag and in-
vitro drug release profile were studied.
Evaluation of FL SMEDDS chronotherapeutics capsules
•	 Rupture Test
The time taken for the coat to rupture was determined 
visually. The SMEDDS capsules were subjected to 
dissolution in USPXXIV dissolution apparatus (Type II), 
using different media at 37 °C; paddle speed being 50 rpm. 
The time lag was defined as the time point at which the 
polymer coating rupture (n=6).
•	 In vitro drug release study
In vitro drug release was carried out in distilled water, 
pH (1.2, 4.5, 6.8, and 7.4) buffers. In order to simulate GIT 
conditions in vivo, the drug release was also carried out in 
sequential buffer change i.e. 1.2 pH buffer (0-2 h), 4.5 pH 
buffer (2-4 h) and followed next by pH 6.8 buffer and then 
by pH 7.4 buffer. The dissolution studies were carried out 
in 500 mL of buffer in USPXXIV dissolution apparatus 
(Type II) (Electrolab TDT-08L, Electrolab, India) paddle 
speed being 50 rpm at 37 ± 0.5 °C. The drug release was 
then determined spectrophotometrically at 362 nm (n=6). 
The linearity concentration for in vitro drug release testing 
was 5-25 µg/ml in all the dissolution media. The linearity 
equation for FL in water, pH 1.2 buffer, pH 4.5 buffer, 
pH 6.8 buffer and pH 7.4 buffer were y = 0.021x - 0.017, 
y = 0.024x-0.008, y = 0.029x + 0.003, y = 0.018x + 0.001 
and y = 0.0217x + 0.0013 respectively.
RESULTS AND DISCUSSION
The self-emulsifying formulations comprising 
oil, surfactants, co-surfactants, and drug should be a 
clear and monophasic liquid at ambient temperature 
when added in to aqueous phase and should have good 
solvent properties to allow visualization of the drug in 
solution (Basalious et al., 2010). Solubility studies were 
aimed at identifying suitable oil phase and surfactant to 
co-surfactant ratio for the development of FL SMEDDS 
formulation. Distinguishing the suitable oil, surfactant to 
co-surfactant ratio having maximal solubilizing potential 
for drug under investigation is very important to achieve 
optimum drug loading (Pouton, 2000; Embleton et al., 
1997). Solubility of FL in different types of oils, surfactant 
and co-surfactant are shown in Figure 2. Solubility studies 
clearly indicated that amongst the various oils that were 
screened, lauroglycol FCC and Labrafill M1944 CS could 
solubilize relatively large amount of FL. Transcutol P (TP) 
was found to be a very efficient solubilizer for FL. As it 
is a very good solubilizer and absorption enhancer and 
FIGURE 2 - Solubility of FL in various oils, Surfactants and 
Co-surfactants.
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thus was chosen as a co-surfactant in the development 
of SMEDDS formulations aiming to improve the drug 
loading capabilities.
The selection of surfactant or co-surfactant in 
the further study was governed by their emulsification 
efficiency and their ability to solubilise FL. Generally, 
surfactants are selected based on the continuous phase 
or disperse phase of the emulsion (hydrophilic surfactant 
for emulsion with aqueous phase as the dispersion phase 
and vice-versa). Since SMEDDS is meant to be diluted 
in aqueous phase to obtain microemulsion, inclusion 
of hydrophilic surfactant is an obvious choice. Among 
the surfactants screened during study, Cremophor EL 
(CEL) was found to give clear systems with lauroglycol 
FCC. The results demonstrated that TP was found to be 
a good co-surfactant in combination with CEL and thus 
it was selected for further studies. We have used CEL 
as surfactant and TP as co-surfactant in different ratios, 
which gives the FL SMEDDS with good emulsification 
and flowability characteristics as shown in Table III.
In the present investigation, lauroglycol FCC was 
tested for phase behavior studies with CEL and TP as 
S/CoS mixture. As seen from the ternary plot (Figure 
3), it was observed that lauroglycol FCC gave a wider 
microemulsion region at all S/CoS ratios. Hence, 
lauroglycol FCC was found to be the preferred vehicle 
for the FL SMEDDS formulation. Figure 3 showed that 
the microemulsion existence was found to be increased by 
some extent with the increasing ratio of S/CoS mixtures. 
These results are in agreement with the observations of 
initial trials of all batches with lauroglycol FCC. However, 
as mentioned above, increasing surfactant ratio resulted in 
loss of flowability. Thus, S/CoS ratio of 2:1 was selected 
for final FL SMEDDS formulation.
Microemulsions resulting from dilution of FL 
SMEDDS with various dissolution media were robust to 
all dilutions and did not show any separation even after 
24 h of storage. The mean globule size of FL SMEDDS 
after dilution with various dissolution media is given in 
Table IV. Optimized FL SMEDDS showed approximately 
similar mean globule size within range of 65-85 nm when 
diluted with various dissolution media of different pH. 
The time required for formation of microemulsions after 
dilution with various dissolution media was less than 4 
min. The resulting microemulsions were translucent in 
appearance and they did not show any signs of phase 
separation and drug precipitation even after 24 h of the 
storage. Thus, the formulated composition was found to 
be stable.
Ethyl cellulose was chosen as the coating polymer 
because of its weak mechanical strength and insolubility 
throughout the gastrointestinal tract. Though a not very 
flexible film is desired, the film formed must be strong 
enough to withstand the in-vivo GIT turbulences and 
remain intact for the period of “time lag”. Therefore, 
various grades of ethyl cellulose differing in their 
viscosities were screened. Figure 4 (a) showed the drug 
release profile of the different batches coated with various 
grades of ethyl cellulose. The release profile indicates 
that as the viscosity of the polymer increases stronger 
and more durable films are formed. The thickness of film 
is not uniform all over the capsules; rupture is occurred 
were film thickness is thin compared to other part of film. 
The grade with the lowest viscosity (Ethyl Cellulose N7) 
showed good mechanical strength and rupture after the 
desired time lag.
Different plasticizers were used along with the 
film-forming polymer to produce good uniform film. 
Ethyl cellulose forms a tough however mechanically 
weak and brittle film and therefore plasticizers are added 
to increase film flexibility and to rupture after the desired 
time lag. Figure 4(b) showed the effect of different types 
of plasticizer on time lag. Hydrophilic plasticizers such as 
PEG 400 gave a very small time lag (~0.33 h). This is due 
to the rapid dissolution of the plasticizer in the medium 
and formation of micro pores in the polymeric film coat 
through which the drug can diffuse out. As the lipophilicity 
of the plasticizer increased, an increase in time lag was 
TABLE III - Effect of surfactant to co-surfactant ratios on particle size, polysdispersity index, zeta potential, clarity and precipitation
S/CoS ratio
Evaluation parameters
Particle size 
(nm)
Polydispersity 
Index 
Zeta potential 
(mV) Clarity Precipitation 
0.5:1.0 231.33 ± 10.2 0.213 ± 0.032 -15 Clear Unstable 
1.0:1.0 150.89 ± 12.3 0.292 ± 0.091 -19 Clear Stable 
1.5:1.0 133.80 ± 7.9 0.119 ± 0.024 -18 Clear Stable 
2.0:1.0 65.230 ± 9.2 0.211 ± 0.031 -13 Clear Stable
S/CoS=Surfactant to Co-surfactant ratio
Design and optimization of self-microemulsifying drug delivery system (SMEDDS) of felodipine for chronotherapeutic application 209
TABLE IV - Globule size and polydispersity index of FL SMEDDS at different pH conditions
Dissolution Medium Water Buffer pH 1.2 Buffer pH 4.5 Buffer pH 6.8
Globule size (nm)a 65.34± 2.3 70.54 ± 8.8 68.45 ± 4.7 76.35 ± 9.2
Polydispersity indexb 0.367± 0.078 0.213 ± 0.063 0.382 ± 0.092 0.213 ± 0.034
a Globule size expressed as mean (n = 3) where relative standard deviation was <10%. b Polydispersity index expressed as mean 
(n = 3).
FIGURE 3 - Ternary phase diagrams of different selected systems dispersed in water at 25 °C. (Oil = lauroglycol FCC, Surfactant 
= Chremophor EL, Co-surfactant = Transcutol P) Ratio of surfactant to cosurfactant in (a) is 0.5:1, (b) is 1:1, (c) is 1.5:1 and (d) 
is 2:1. Dark area shows oil in water microemulsion region.
observed. Films plasticized with dibutyl phthalate (DBP) 
gave desirable time lag (~6.0 h) and subsequently desired 
in-vitro drug release profile. Hence, DBP was chosen as 
the plasticizer to get the desired drug release.
Increase in the coat thickness also cause resistance to 
the water penetration and coat rupture. Figure 5 (a) showed 
that with increase in the percent coating weight gain i.e. 
with increase in coat thickness there was a corresponding 
increase in the time lag of the formulation indicating that 
this parameter could be used to modulate and achieve a 
desired time lag. The desired released profile was obtained 
by 10% weight gain of the polymer coat. pH independent 
drug release behaviour of the polymer was also studied by 
carrying out the dissolution in sequential buffer change. 
As shown in Figure 5(b), drug release behaviour of the 
optimized formulation was found to be not affected by 
the pH of the medium. Thus, the developed formulation 
was showing pH independent release profile of FL owing 
to the use of ethyl cellulose as hydrophobic functional 
coating material.
CONCLUSIONS
The most significant issue to consider when 
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formulating chronotherapeutics delivery is to release 
drugs after a defined delay period (lag period-interval of 
no drug release) after being taken by the patient. Here, 
we have successfully developed SMEDDS of Felodipine 
to increase the bioavailability and filled in hard gelatine 
capsules coated with pH independent polymer. Thus, 
time dependent release of drug from the formulation to a 
specific time of the day was successfully achieved when 
there is maximal clinical manifestation of the disease.
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